Studies immune cells called macrophages in people with ALS
Compares macrophage markers in ALS patients, controls and gene carriers.
Plain-language title generated from the registry record
Registry title: Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Département de Neurologie, Hôpital de la Pitié-SalpêtrièreParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut National de la Santé Et de la Recherche Médicale, France
- Trial code
- NCT04816227
- Record updated
- 9 March 2026
- Original description
The aim of this project is to analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals, patients with other motor impairments) and asymptomatic ALS gene carriers, to find new pathways for therapeutic targets and disease biomarkers.Read full original descriptionShow less
Expression Profile Study of Macrophages From Patients Affected by Amyotrophic Lateral Sclerosis (ALS) or Other Related Motor Impairments
The aim of this project is to analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals, patients with other motor impairments) and asymptomatic ALS gene carriers, to find new pathways for therapeutic targets and disease biomarkers.
Inclusion: Agree to participate in this research and have signed an informed consent; Be able to understand the objectives and procedures of the study; Be affiliated to French social security or equivalent; Meet one of the criteria below:; (i) Be affected by Amyotrophic Lateral Sclerosis (ALS) definite, probable or possible (El Escorial criteria) sporadic SALS (no known history in the family) or familial FALS (at least one other member of the family affected), (ii) not being affected by ALS but having a close relative who has or has been diagnosed with ALS and has or is a carrier of a known mutation causing ALS and has consented to a genetic analysis, (iii) Have a motor impairment including the following pathologies: Motor neuropathy, myopathy, Myositis, Spastic paraplegia, Cram / fasciculation syndrome, Chronic inflammatory polyradiculitis, somatization disorder, Anterior spinal artery syndrome, encephalitis, myelitis, Peroneal neuropathy, cervical myelopathy with radiculopathy, spinocerebellar ataxia, Kennedy disease, Spinal atrophy, Hereditary distal motor neuropathy; (iv) be accompanying a person with ALS or other motor impairment that is followed by one of the doctors from the ALS referral center at the Pitié-Salpêtrière hospital or by a neurologist from the neurophysiology department at the Pitié-Salpêtrière hospital.
Exclusion: Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research; Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship); Refusing to participate in the study; Being pregnant or breastfeeding.